DATE: October 7, 2026 at 11:18AM
SOURCE: PSYCHIATRIC TIMES
Direct article link at end of text block below.
The FDA has cleared Motivista, a prescription digital therapeutic indicated for the negative symptoms of schizophrenia, as an adjunct to outpatient care. This is the first authorized treatment for negative symptoms of schizophrenia in the United States. https://t.co/JqKYf8JfD2
Here are any URLs found in the article text:
Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #SchizophreniaTreatment #DigitalTherapeutics #FDAApproved #NegativeSymptoms #MentalHealthCare